Ownership and insider activity for Karyopharm Therapeutics Inc. (KPTI): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses.
Price
| Price | $1.70 |
| Market Cap | $39M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-01 | Abate Kristin | S-Sale | 19 | $38 |
| 2026-07-28 | Poulton Stuart | S-Sale | 189 | $1K |
| 2026-05-21 | Oliger Christy J. | A-Award | 15,508 | |
| 2026-05-21 | PAKIANATHAN DEEPIKA | A-Award | 15,508 | |
| 2026-05-21 | Schor Chen | A-Award | 15,508 | |
| 2026-05-21 | Su Zhen | A-Award | 15,508 | |
| 2026-05-21 | BOHLIN GAREN G | A-Award | 15,508 | |
| 2026-05-21 | Greene Barry E | A-Award | 15,508 | |
| 2026-05-13 | Poulton Stuart | A-Award | 896 | |
| 2026-05-14 | Poulton Stuart | S-Sale | 403 | $4K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $49.7M | $69.0M | $118.0M | $128.9M | $85.9M | $190.5M | $135.2M | $52.2M | $62.5M | $60.5M |
| Short-term Investments | $79.9M | $77.5M | $210.2M | $133.1M | $163.3M | $38.2M | $142.8M | $139.2M | $46.2M | $3.2M |
| Receivables | 0 | 0 | 0 | $7.9M | $12.9M | $22.5M | $47.1M | $27.0M | $30.8M | $26.2M |
| Inventory | 0 | 0 | 0 | $346000 | $2.6M | $4.1M | $4.2M | $3.0M | $4.7M | $4.0M |
| Total Current Assets | $131.6M | $148.4M | $334.6M | $278.6M | $276.5M | $275.6M | $350.2M | $233.9M | $156.5M | $103.1M |
| Property, Plant & Equipment | $2.8M | $2.2M | $3.9M | $13.7M | $11.6M | $9.6M | $7.4M | $4.9M | $6.3M | $4.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $180.4M | $180.3M | $341.2M | $295.0M | $313.1M | $305.3M | $358.2M | $240.4M | $164.4M | $108.4M |
| Accounts Payable | $4.8M | $5.7M | $4.3M | $985000 | $4.5M | $1.6M | $2.8M | $3.1M | $5.1M | $4.0M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $24.4M | $21.0M |
| Total Current Liabilities | $16.5M | $49.5M | $46.9M | $46.4M | $60.2M | $73.7M | $65.9M | $69.5M | $92.3M | $92.1M |
| Long-term Debt | 0 | 0 | $102.7M | $109.9M | $117.9M | $169.3M | $170.1M | $170.9M | $162.9M | $205.9M |
| Total Liabilities | $18.1M | $50.8M | $158.0M | $245.2M | $262.5M | $385.0M | $374.8M | $376.6M | $350.4M | $401.3M |
| Retained Earnings | -$366.1M | -$495.3M | -$673.7M | -$873.3M | -$1.07B | -$1.18B | -$1.34B | -$1.49B | -$1.56B | -$1.76B |
| Total Equity | $162.2M | $129.5M | $183.2M | $49.8M | $50.5M | -$79.7M | -$16.7M | -$136.2M | -$186.0M | -$292.9M |
| Total Debt | 0 | 0 | $102.7M | $124.7M | $131.1M | $180.6M | $179.1M | $177.0M | $194.5M | $233.6M |
| Net Debt | -$129.6M | -$146.5M | -$225.5M | -$137.3M | -$118.1M | -$48.0M | -$98.9M | -$14.4M | $85.8M | $169.9M |
| Working Capital | $115.2M | $99.0M | $287.7M | $232.2M | $216.3M | $201.9M | $284.3M | $164.4M | $64.2M | $11.1M |
Financial Health
| Debt / Equity | -0.65 |
| Current Ratio | 0.79 |
Profitability
| Return on Equity | 77.63% |
| Return on Invested Capital | 376.87% |
| Return on Assets | -201.89% |
| Gross Margin | 95.88% |
| Operating Margin | -56.17% |
| Net Margin | -153.28% |
Related companies: ALGS · BRNS · CVM · FGEN · INMB · MDCX · MRSN
Explore sector: Healthcare · Biotechnology
More sections of KPTI: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks